Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Tables)

v3.22.4
Segment Reporting (Tables)
12 Months Ended
Nov. 30, 2022
Segment Reporting [Abstract]  
Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, and assets for the years ended November 30, 2022 and November 30, 2021:

 

 

 

For the years ended November 30,

 

 

 

2022

 

 

2021

 

Net revenue:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

29,771,123

 

 

$

28,397,401

 

PrepaCyte CB

 

 

104,000

 

 

 

111,400

 

Public cord blood banking

 

 

461,626

 

 

 

376,101

 

Total net revenue

 

$

30,336,749

 

 

$

28,884,902

 

Cost of sales:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

7,095,113

 

 

$

7,351,410

 

PrepaCyte CB

 

 

100,715

 

 

 

154,140

 

Public cord blood banking

 

 

1,596,530

 

 

 

1,484,186

 

Total cost of sales

 

$

8,792,358

 

 

$

8,989,736

 

Operating profit:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

5,185,305

 

 

$

6,362,172

 

PrepaCyte CB

 

 

(24,493

)

 

 

(70,335

)

Public cord blood banking

 

 

(1,136,345

)

 

 

(2,273,604

)

Total operating profit

 

$

4,024,467

 

 

$

4,018,233

 

Depreciation and amortization:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

1,090,309

 

 

$

806,230

 

PrepaCyte CB

 

 

27,778

 

 

 

27,595

 

Public cord blood banking

 

 

1,441

 

 

 

1,020

 

Total depreciation and amortization

 

$

1,119,528

 

 

$

834,845

 

Interest expense:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

1,521,767

 

 

$

1,378,926

 

PrepaCyte CB

 

 

 

 

 

 

Public cord blood banking

 

 

 

 

 

 

Total interest expense

 

$

1,521,767

 

 

$

1,378,926

 

 

 

 

 

 

 

 

 

The following table shows the assets by segment as of November 30, 2022 and November 30, 2021:

 

 

 

2022

 

 

2021

 

Assets:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell
   service

 

$

54,849,697

 

 

$

50,170,887

 

PrepaCyte CB

 

 

176,546

 

 

 

250,591

 

Public cord blood banking

 

 

9,861,811

 

 

 

10,240,598

 

Total assets

 

$

64,888,054

 

 

$

60,662,076